Evidence map›Paper›PMID 26643655›Full record

ReviewExpert review of gastroenterology & hepatology2016

Novel approaches to treating Clostridium difficile-associated colitis.

David Padua, Charalabos Pothoulakis

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Expert review of gastroenterology & hepatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Pathogens (Basel, Switzerland) · 2020
    Article
  5. Review
  6. Intraluminal Administration of Resiniferatoxin Protects againstGastroenterology research and practice · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

David Paduaa Department of Medicine , University of California, Los Angeles , Los Angeles , CA , USA.
Charalabos Pothoulakisa Department of Medicine , University of California, Los Angeles , Los Angeles , CA , USA.

Funding

Pilot and Feasibility ProgramP30DK041301 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ROZENGURT, JUAN ENRIQUE · 1990 to 2019
$18.0M
Women's Health and Functional Visceral Disorders CenterP50DK064539 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MAYER, EMERAN A · 2002 to 2017
$17.5M
GASTROENTEROLOGYT32DK007180 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI JENSEN, DENNIS MICHAEL · 1986 to 2025
$10.0M
Mechanisms of Neurotensin in Intestinal InflammationR01DK060729 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI POTHOULAKIS, CHARALABOS · 2002 to 2017
$5.0M
SUBSTANCE P AND INTESTINAL INFLAMMATIONR01DK047343 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI POTHOULAKIS, CHARALABOS · 1994 to 2014
$4.2M
NIDDK NIH HHS 1P50 DK64539NIDDK NIH HHS P30 DK041301NIDDK NIH HHS P30 DK 41301NIDDK NIH HHS P50 DK064539NIDDK NIH HHS R01 DK047343NIDDK NIH HHS R01 DK060729NIDDK NIH HHS T32 DK007180NIDDK NIH HHS T32 DK07180-40
6 · The paper itself

Abstract

Clostridium difficile is being recognized as a growing threat to many health-care systems. Epidemiology data shows that infection rates are soaring and the disease burden is increasing. Despite the efficacy of standard treatments, it is becoming evident that novel therapeutics will be required to tackle this disease. These new treatments aim to enhance the intestinal microbial barrier, activate the immune system and neutralize the toxins that mediate this disease. Many of these therapies are still in the beginning stages of investigation, however, in the next few years, more clinical data will become available to help implement many of these exciting new therapeutic approaches.

Indexed as

Fecal Microbiota TransplantationGastrointestinal MicrobiomeAnimalsAnti-Bacterial AgentsBacterial VaccinesClostridioides difficileClostridium InfectionsColitisHumansIntestinesProbioticsTreatment OutcomeAnti-Bacterial AgentsBacterial VaccinesClostridium difficilefecal microbial transplantnovel therapeuticsprobioticsvaccine therapy

Identifiers

PMID26643655
PMCPMC5979265

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.